Filtered By:
Procedure: Heart Transplant
Therapy: Stem Cell Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 41 results found since Jan 2013.

Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research
Conclusion The high prevalence of comorbidities in patients with stroke indicates the need for therapies in preclinical studies that take into account these comorbidities in order to avoid failures in translation to the patient. Preclinical studies are beginning to evaluate the efficacy of MSC treatment in stroke associated with comorbidities, especially hypertension, for ischemic and hemorrhagic stroke. Regarding aging and diabetes, only ischemic stroke studies have been performed. For the moment, few studies have been performed and contradictory results are being reported. These contradictory results may be due to the u...
Source: Frontiers in Neurology - April 8, 2019 Category: Neurology Source Type: research

Stroke Dysbiosis Index (SDI) in Gut Microbiome Are Associated With Brain Injury and Prognosis of Stroke
Conclusions: We developed an index to measure gut microbiota dysbiosis in stroke patients; this index was significantly correlated with patients' outcome and was causally related to outcome in a mouse model of stroke. Our model facilitates the potential clinical application of gut microbiota data in stroke and adds quantitative evidence linking the gut microbiota to stroke. Introduction Ischemic stroke imposes a heavy burden on society, with 24.9 million cases worldwide (1). Although intravenous thrombolysis and endovascular treatment greatly improve some patients' prognosis, the prognosis for most pa...
Source: Frontiers in Neurology - April 23, 2019 Category: Neurology Source Type: research

World-Wide Efficacy of Bone Marrow Derived Mesenchymal Stromal Cells in Preclinical Ischemic Stroke Models: Systematic Review and Meta-Analysis
Conclusions: Our results show worldwide efficacy of BM-MSCs in improving functional outcomes in pre-clinical animal models of stroke and support testing these cells in clinical trials in various ranges of time windows using different delivery routes. The continued growing number of publications showing functional benefit of BM-MSCs are now adding limited value to an oversaturated literature spanning 18 years. Researchers should focus on identifying definitive mechanisms on how BM-MSCs lead to benefit in stroke models. Introduction Ischemic stroke is the 5th leading cause of death and the leading cause of long term di...
Source: Frontiers in Neurology - April 23, 2019 Category: Neurology Source Type: research

Using Dental Pulp Stem Cells for Stroke Therapy
Conclusion and Future Perspectives Stem cell-based therapy is a promising alternative for stroke treatment. While stem cells from different sources, including induced PSC, ESC, MSC, and NSC, have been investigated, using NSC and enhancing the natural mechanisms is most appropriate for brain repair. In preclinical models of stroke, stem cell transplantation has led to positive outcomes through a variety of cellular and molecular mechanisms, many being mediated by the array of beneficial factors produced by the cells. Recent advances in cellular reprogramming have provided alternative sources of NSC to be investigated, allo...
Source: Frontiers in Neurology - April 28, 2019 Category: Neurology Source Type: research

Endothelial Progenitor Cells: Therapeutic Perspective for Ischemic Stroke.
Abstract Endothelial progenitor cells (EPCs), which can be cultured in vitro from mononuclear cells in peripheral blood or bone marrow, express both hematopoietic stem cell and endothelial cell markers on their surface. They are believed to participate in endothelial repair and postnatal angiogenesis due to their abilities of differentiating into endothelial cells and secreting protective cytokines and growth factors. Mounting evidence suggests that circulating EPCs are reduced and dysfunctional in various diseases including hypertension, diabetes, coronary heart disease, and ischemic stroke. Therefore, EPCs have ...
Source: CNS Neuroscience and Therapeutics - December 11, 2012 Category: Neuroscience Authors: Zhao YH, Yuan B, Chen J, Feng DH, Zhao B, Qin C, Chen YF Tags: CNS Neurosci Ther Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Stem Cells for Cell-Based Therapies
The world of stem cells We know the human body comprises many cell types (e.g., blood cells, skin cells, cervical cells), but we often forget to appreciate that all of these different cell types arose from a single cell—the fertilized egg. A host of sequential, awe-inspiring events occur between the fertilization of an egg and the formation of a new individual: Embryonic stem (ES) cells are also called totipotent cells. The first steps involve making more cells by simple cell division: one cell becomes two cells; two cells become four cells, etc. Each cell of early development is undifferentiated; that is, it is...
Source: ActionBioscience - December 28, 2012 Category: Science Authors: Ali Hochberg Source Type: news

Stem cells: what happened to the radical breakthroughs?
Much was promised in the late 1990s, but the challenge of advances such as growing whole human organs has been difficult to deliverIt's 1998 and science is taking big strides. The first cloned mammal, Dolly the Sheep, has just had her first lamb; the first robotically assisted heart surgery has been completed; Furbys have hit the shelves. In a bold announcement, biomedical engineer Professor Michael Sefton declared that within 10 years, scientists would have grown an entire heart, fit for transplant. "We're shooting big," he said. "Our vision is that we'll be able to pop out a damaged heart and replace it as easily as you ...
Source: Guardian Unlimited Science - August 10, 2013 Category: Science Authors: Simon Roach Tags: Biology Medical research Features Stem cells The Observer Science Source Type: news

Disrupting Today's Healthcare System
This week in San Diego, Singularity University is holding its Exponential Medicine Conference, a look at how technologists are redesigning and rebuilding today's broken healthcare system. Healthcare today is reactive, retrospective, bureaucratic and expensive. It's sick care, not healthcare. This blog is about why the $3 trillion healthcare system is broken and how we are going to fix it. First, the Bad News: Doctors spend $210 billion per year on procedures that aren’t based on patient need, but fear of liability. Americans spend, on average, $8,915 per person on healthcare – more than any other count...
Source: Healthy Living - The Huffington Post - November 9, 2015 Category: Consumer Health News Source Type: news

Transfusion strategy in hematological intensive care unit: study protocol for a randomized controlled trial
Background: Packed red blood cell (PRBC) transfusion is required in hematology patients treated with chemotherapy for acute leukemia, autologous (auto) or allogeneic (allo) hematopoietic stem cell transplantation (HSCT). In certain situations like septic shock, hip surgery, coronary disease or gastrointestinal hemorrhage, a restrictive transfusion strategy is associated with a reduction of infection and death. A transfusion strategy using a single PRBC unit has been retrospectively investigated and showed a safe reduction of PRBC consumption and costs. We therefore designed a study to prospectively demonstrate that the tra...
Source: Trials - November 23, 2015 Category: Journals (General) Authors: Sylvain ChantepieJean-Baptiste MearLydia GuittetBenoît DervauxJean-Pierre MarolleauFabrice JardinJean-Jacques DutheilJean-Jacques ParientiJean-Pierre VilqueOumedaly Reman Source Type: research

Quantitative Magnetic Particle Imaging Monitors the Transplantation, Biodistribution, and Clearance of Stem Cells In Vivo
Stem cell therapies have enormous potential for treating many debilitating diseases, including heart failure, stroke and traumatic brain injury. For maximal efficacy, these therapies require targeted cell delivery to specific tissues followed by successful cell engraftment. However, targeted delivery remains an open challenge. As one example, it is common for intravenous deliveries of mesenchymal stem cells (MSCs) to become entrapped in lung microvasculature instead of the target tissue. Hence, a robust, quantitative imaging method would be essential for developing efficacious cell therapies. Here we show that Magnetic Par...
Source: Theranostics - June 5, 2016 Category: Molecular Biology Authors: Bo Zheng, Marc P. von See, Elaine Yu, Beliz Gunel, Kuan Lu, Tandis Vazin, David V. Schaffer, Patrick W. Goodwill, Steven M. Conolly Tags: Research Paper Source Type: research

Reflections on the Future of Medicine
Recently, I traveled through China. I climbed mountains, hiked through forests, crossed deep valleys. I visited cities of every size. I floated across lakes and traveled beautiful shorelines churning with life. As a man of a certain age, I began to compare the permanence of the timeless landscape with the evanescence of my own existence. Yet, as a scientist, I knew these reflections were flawed. Scientists are trained to think in terms of aeons, millenia, and lifetimes. Consider the paradox. Is it the solid mountain or fragile the forest that is permanent? Is it the massive shoreline cliffs or the teeming shore life that...
Source: Science - The Huffington Post - January 9, 2017 Category: Science Source Type: news

Sustaining and Improving Current Practices Surrounding Timely Hypertension Management in Pediatric Hematopoietic Stem Cell Patients
Topic Significance& Study Purpose/Background/Rationale: Hypertension (HTN) is a known complication during pediatric hematopoietic stem cell transplant (HSCT). The risks for developing hypertension depend on a variety of factors including the use of drugs (calcineurin inhibitors, steroids, and chemotherapy), total body irradiation (TBI), renal injury, transplant associated thrombotic microangiopathy (TMA) and sinusoidal obstructive syndrome (SOS). Uncontrolled HTN may lead to significant life-threatening complications including impaired renal and heart function, stroke, posterior reversible encephalopathy (PRES) and death.
Source: Biology of Blood and Marrow Transplantation - February 22, 2017 Category: Hematology Authors: Michelle Lewyckyj, Adam S. Nelson, Christopher E. Dandoy, Ashley Teusink, Sonata Jodele, Laura Flesch Source Type: research